Calendario›SNY›Real World and Epidemiology Study of Medically Attended Chlamydia Trachomatis Among Adults in Germany
Real World and Epidemiology Study of Medically Attended Chlamydia Trachomatis Among Adults in Germany
Ensayo de Sanofi en Chlamydia Trachomatis (del registro, en inglés).
- Fase
- no aplica
- Estado
- Completado
- Participantes
- 81.239
- Centros
- 1
- Fin del objetivo primario
- dic 2025
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en mar 2025.
Qué mide
Number of female participants with documented (confirmed) outpatient or any inpatient of pelvic inflammatory disease (PID) (From Year 2008 to Year 2022) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis study assesses the epidemiologic situation of chlamydia trachomatis, its complications and long term sequalae and related healthcare resource utilization and costs among adults in Germany. The study is a retrospective cohort study based on German Statutory Health Insurance (SHI) claims data for adolescents and adults aged 14 to 44 years in the years 2008-2022 with documented (confirmed) diagnosis of CT. Study Objectives are to: 1. Estimate frequency of potential short-term complications and long-term sequelae in patients with medically attended chlamydia infection 2. Analyze time from first documented prevalent CT infection to first potential complication/sequelae diagnosis 3. Estimate frequency of re-infection (chlamydia recurrence) and co-infections with other sexually transmitted infections (STIs) in patients with medically-attended chlamydia infection 4. Estimate absolute healthcare resource utilization (by level of care and specialty) and costs in patients with chlamydia infection, including for potential short-term complications and long-term sequelae 5. Estimate administrative prevalence of medically-attended chlamydia infection in the overall study population 6. Estimate administrative prevalence of diagnoses potentially associated with a chlamydia infection (i.e., short-term complications/long-term sequelae) in the overall study population 7. Estimate frequency of chlamydia testing in the overall study population
Más ensayos de SNY
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Avalglucosidase alfa · Mini-COMET | Fase 2 | En marcha, sin reclutar | sep 2019 (real) |
| Yellow fever vaccine | Fase 2 | En marcha, sin reclutar | may 2022 (real) |
| Yellow fever vaccine · VYF02 | Fase 2 | En marcha, sin reclutar | jun 2022 (real) |
| SAR441344 IV | Fase 2 | En marcha, sin reclutar | sep 2022 (real) |
| Meningococcal Polysaccharide | Fase 3 | En marcha, sin reclutar | mar 2023 (real) |
| Isatuximab IV · IRAKLIA | Fase 3 | En marcha, sin reclutar | nov 2024 (real) |
Todos los de SNY, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT07002047), actualizada en abr 2026.